ASP3652: Clinical Trials

6 completed. 6 Phase 1.

By phase and status

Phase	Trials	Status
Phase 1	6	Completed 6

Follow ASP3652: new trials by email Literature Review of ASP3652 trials Research Report on ASP3652

Trials (filtered) newest first · largest first

All 6 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
A Study to Investigate the Appearance and Disappearance of ASP3652 in Blood and Spinal Fluid in Healthy Male Subjects ASP3652 - Pharmacokinetics of ASP3652, Pharmacodynamics of ASP3652	Phase 1	Completed	Astellas Pharma Europe B.V.	14	2012-09-01	2014-01-13
A Study to Assess the Safety, Tolerability and Effects of Single Ascending Doses of ASP3652 in Healthy Subjects ASP3652, Placebo - Pharmacokinetics, Pharmacodynamics	Phase 1	Completed	Astellas Pharma Europe B.V.	26	2012-08-01	2013-03-21
A Study to Assess the Effect of Race on How a Single Dose of ASP3652 is Taken up, Metabolized and Distributed Through the Bodies of Young, Healthy Male and Female Subjects, and Its Safety and Tolerability ASP3652 - Pharmacokinetics, Pharmacodynamics	Phase 1	Completed	Astellas Pharma Europe B.V.	64	2012-07-01	2013-10-08
A Study to Assess the Pharmacokinetics, Metabolism and Excretion Routes of ASP3652 in Man, After Administration of 14C Radio Labeled ASP3652 ASP3652 - Healthy Subjects, Pharmacokinetics of ASP3652	Phase 1	Completed	Astellas Pharma Europe B.V.	6	2012-07-01	2014-01-28
A Study to Assess the Effect of Multiple Doses of Gemfribozil on a Single Dose of ASP3652, and to Assess the Effects of Multiple Doses of ASP3652 on a Single Dose of Repaglinide in the Body of Healthy Subjects ASP3652, Gemfibrozil, Repaglinide - Drug-Drug Interaction (DDI), Healthy Subjects	Phase 1	Completed	Astellas Pharma Europe B.V.	48	2012-04-01	2013-02-22
A Study to Assess the Safety, Tolerability, and Effects in and on the Body of Healthy Young and Elderly Male and Female Subjects of Ascending Multiple Oral Doses of ASP3652 ASP3652, Placebo - Healthy Subjects, Pharmacokinetics of ASP3652	Phase 1	Completed	Astellas Pharma Europe B.V.	101	2009-05-01	2014-09-18

Conditions studied

Coitus (1)

Sponsors

Astellas Pharma Europe B.V. (6)

Countries

United Kingdom (4)  ·  Netherlands (2)

Results publications

PMID 32715381

NIH funding

2008 (1)